NCT06698250 (ZENOBIA) is a Phase 2 clinical trial of Zanzalintinib in Hepatocellular Carcinoma, sponsored by Anwaar Saeed.

Who is sponsoring NCT06698250?

NCT06698250 is sponsored by Anwaar Saeed.

What drugs are being tested in NCT06698250?

Interventions in NCT06698250: Zanzalintinib, Durvalumab, Tremelimumab.

What condition does NCT06698250 study?

NCT06698250 studies Hepatocellular Carcinoma.

Is NCT06698250 still recruiting?

NCT06698250 is currently recruiting now. Last updated 6 November 2025.

Last reviewed 2025-11-06 · How we verify

NCT06698250: ZENOBIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Recruiting now Phase 2 Last updated 6 November 2025

What this trial tests

Phase 2 trial testing Zanzalintinib in Hepatocellular Carcinoma in 40 participants. Currently enrolling.

Timeline

18 December 2024

Primary endpoint
31 December 2026

30 April 2027

Quick facts

Lead sponsor	Anwaar Saeed
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	18 December 2024
Primary completion	31 December 2026
Estimated completion	30 April 2027
Sites	3 locations across United States

Drugs / interventions tested

Zanzalintinib — full drug profile →
Durvalumab — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Anwaar Saeed

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic eﬀect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Application of Immune Checkpoint Inhibitors in Cancer.
Chen Z, Song Z, Den S, Zhang W, et al · · 2025 · cited 2× · PMID 40787068 · DOI 10.1002/mco2.70176
The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy.
Lv Y, Duan T, Song J, Liu S, et al · · 2026 · cited 1× · PMID 41625480 · DOI 10.34133/cancomm.0002

Verify or expand the search:

Other trials of Zanzalintinib

Trials testing the same drug.

NCT07527169 — A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma · Phase 2 · not yet recruiting
NCT07470489 — Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer · Phase 2 · not yet recruiting
NCT07283731 — Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma · Phase 2 · recruiting
NCT07489495 — A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-0 · Phase 3 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Anwaar Saeed trials

Trials by the same sponsor.

NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
NCT06006923 — Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer · Phase 2 · terminated
NCT05239182 — 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma · Phase 2 · terminated
NCT03539822 — Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointes · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06698250 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anwaar Saeed
Last refreshed: 6 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06698250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing